Alvotech’s poster titled “A clinical study designed to support a demonstration of interchangeability between AVT02 and Humira®” will be in the Virtual Poster Room on Saturday, November 12, 2022, from 1:00 p. m. m. at 15:00 ET (ET).
A poster titled “Ex vivo comparative immunogenicity assessment (EVCIA) to determine relative immunogenicity in chronic plaque psoriasis in participants receiving Humira or undergoing repeated changes between Humira® and AVT02” will be presented in the Virtual Poster Room on Sunday, November 13, 2022. from 9:00 am to 10:00 am ET.
On Monday, November 14, 2022 at 2:15 p. m. , ET, Steve Feldman, M. D. , Ph. D. , Professor of Dermatology, Wake Forest University School of Medicine, will deliver a center-level Ignite lecture titled “A Clinical Study Designed to Support a Demonstration of Interchangeability between AVT02 and Reference Adalimumab (Humira®). “
The posters and main points of the presentation will be available on the convention platform. More information about the EAC’s Convergence 2022 convention can be found here.
About AVT02 (adalimumab)AVT02 is a monoclonal and biosimilar antibody approved for Humira® (adalimumab) in the EU, the United Kingdom, Switzerland, Norway, Iceland, Lichtenstein (Hukyndra®) and Canada (Simlandi™). AVT02 files are under review in several countries, adding United States.
About Alvotech
Alvotech is a biotechnology company, founded through Robert Wessman, whose sole purpose is to develop and produce biosimilar medicines for patients around the world. Alvotech seeks to be a global leader in the area of biosimilars by offering high-quality, cost-effective products and facilities enabled through a fully embedded technique and extensive in-house capabilities. Alvotech’s existing portfolio comprises 8 applicants for biosimilars for the treatment of autoimmune disorders, eye disorders, osteoporosis, respiratory diseases and cancer. Alvotech has formed a network of strategic business partnerships to deliver global success and leverage local expertise in markets including the United States, Europe, Japan, China and other Asian countries and major parts of South America, Africa and the Middle East. Alvotech’s business components are Teva Pharmaceuticals, a US subsidiary of Teva Pharmaceutical Industries Ltd. (USA), STADA Arzneimittel AG (EU), Fuji Pharma Co. , Ltd (Japan), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co. , Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tutor and Saval (Latin America), and Lotus Pharmaceuticals Co. , Ltd. (Thailand, Vietnam, the Philippines and South Korea). Each business component covers a unique set of products and territories. Except as otherwise stated herein, Alvotech is not responsible for the content of periodic presentations, disclosures and other reports made to be obtained through its components. For more information, make a stopover at www. alvotech. com. None of the data on Alvotech’s online page deserves to be considered as part of this press release.
Forward-Looking Statements Through Alvotech Certain statements contained in this release may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1955, as amended. Forward-looking statements sometimes relate to long-term events or Alvotech’s long-term operational monetary functionality. For example, Alvotech’s expectations related to competitive advantages, business customers, and opportunities, aggregating continued product progression, long-term plans and intentions, effects, point of activities, functionality, goals, or long-term achievements or other occasions, regulatory review and intermediate moves, the good fortune of its trade associations, the outlook and timing of approvals and advertising launches of its product applicants, adding for AVT02, the estimated length of the addressable market position of Alvotech’s general tubing products, and the prospect of Alvotech’s tubing products, adding AVT02, to reduce healthcare costs and build improved patient access to biologic therapies. In some cases, you can identify forward-looking statements by words such as “possibly”, “deserve”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict” , “prospective”, “target” or “continue”, or the negative terms of those terms or variations thereof or similar terminology. These forward-looking statements are subject to risks, uncertainties and other matters that may also cause actual effects to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based on estimates and assumptions that, while believed by Alvotech and its management to be conservative, are inherently doubtful and are inherently related to hazards, variskill and contingencies, many of which are beyond Alvotech’s control. Alvotech. Factors that may also cause actual effects to differ materially from existing expectations include, but are not limited to: (1) the ultimate results of any legal proceedings that could possibly be brought against Alvotech or others as a result of the combination between Alvotech Holdings S. A. , Oaktree Acquisition Corp. II and Alvotech; (2) the ability to maintain inventory exchange directory standards; (3) adjustments in applicable legislation or regulations; (4) the option that Alvotech may be adversely affected by other economic, commercial and/or competitive points; (5) Estimates of expenses and profitability of Alvotech; (6) Alvotech’s ability to develop, manufacture and advertise the products and product applicants in its portfolio; (7) moves by regulatory authorities, which could potentially initiate, schedule and progress clinical studies or long-term regulatory approvals or market positioning authorizations; (8) the ability of Alvotech or its partners to recruit and retain patients in clinical studies; (9) the ability of Alvotech or its partners to download regulatory approvals for planned clinical studies, review plans or sites; (10) the ability of Alvotech’s partners to conduct, supervise and monitor existing and prospective long-term clinical studies, which could possibly have an effect on programs and progression plans; (11) Alvotech’s ability to download and maintain regulatory approvals or authorizations for its products; (12) the good fortune of Alvotech’s existing and long-term collaborations, joint ventures, partnerships or license agreements; (13) Alvotech’s and its business partners’ ability to execute on their approved product advertising strategy, adding AVT02; (14) Alvotech’s ability to manufacture a sufficient source of advertising for its approved products, adding AVT02; (15) the final results of pending and long-term litigation related to Alvotech’s products and product applicants; (16) the potential impact of the ongoing COVID-19 pandemic on FDA review timelines, adding to its ability to conduct timely inspections of production sites; and (17) other dangers and uncertainties set forth in the sections entitled “Risk Factors” and “Caution Regarding Forward-Looking Statements” in the documents that Alvotech may file from time to time with the SEC. There may be additional hazards of which Alvotech is not aware or which Alvotech believes are immaterial and which may also cause actual effects to differ from those contained in forward-looking statements. Nothing in this communication should be taken as a representation that the forward-looking statements set forth herein will be known or that any weighted effects will be achieved by such forward-looking statements. You deserve not to place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech assumes no legal responsibility to update such forward-looking statements or to notify the recipient of any matter known to it that may be any matter referred to in this communication. Alvotech disclaims all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any user or entity as a result of anything contained or overlooked in this communication and such liability is expressly disclaimed. The recipient agrees not to seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, consultants or representatives liable for the provision of this communication, the data contained in this communication, or the omission of any data of this communication.
CONTACTS
AlvotechBenedikt Stefansson’s Global Communications and Investor Relations alvotech. ir[at]alvotech. com
© 2022 Benzinga. com. Benzinga provides investment advice. All rights reserved.